Allogene Therapeutics Net Tangible Assets

Allogene Therapeutics (ALLO) currently reports a net tangible assets of $280M as of March 2026. That compares with $390M in the prior-year period — down 27.6% year over year. Use the charts on this page to explore Allogene Therapeutics's net tangible assets history and peer comparisons.

Allogene Therapeutics's net tangible assets decreased from $390M to $280M — a 27.6% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Allogene Therapeutics reported $280M in net tangible assets as of March 2026. That compares with $390M in the prior-year period — down 27.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $280M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Allogene Therapeutics, and consider following ALLO for alerts when major investors trade the stock.

Allogene Therapeutics is classified in the Healthcare sector. On net tangible assets, it currently shows $280M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALLO with unrelated industries.